Objectives: In the heterogeneous group of preterm and term neonates, gentamicin and tobramycin are mainly dosed according to empirical guidelines, after which therapeutic drug monitoring and subsequent dose adaptation are applied. In view of the variety of neonatal guidelines available, the purpose of this study was to evaluate target concentration attainment of these guidelines, and to propose a new model-based dosing guideline for these drugs in neonates.
Introduction
In the heterogeneous group of preterm and term neonates, gentamicin and tobramycin are mainly dosed according to empirically based dosing guidelines (see e.g. 1 -4 ), after which therapeutic drug monitoring (TDM) is applied and the dose potentially adapted. Whereas empirical dosing guidelines improve incrementally, a model-based dosing guideline can directly indicate the best treatment protocols for reaching target concentrations based on the available knowledge of the drug, therefore reducing the need for trial and error. While many dosing guidelines 1 -4 and pharmacokinetic models exist for gentamicin and tobramycin, the models have only rarely been translated to clinical practice. 5, 6 Recently, a developmental model for the neonatal pharmacokinetics of amikacin was constructed and validated with external datasets that were not used in model building. 7 This model was subsequently extended to other renally cleared antibiotics such as netilmicin, vancomycin, tobramycin and gentamicin. This neonatal pharmacokinetic model was derived from data from 2437 neonates covering a wide range of birth weights (390 -5200 g), which were used as predictors of antenatal maturation, and the whole range of post-natal ages, which were used as predictors of post-natal maturation. 7, 8 The goal of this study was to evaluate the performance of neonatal dosing guidelines for gentamicin and tobramycin of the Dutch National Formulary for Children (DNFc), 1 (Tables S1 and S2 , available as Supplementary data at JAC Online). The percentages of peak and trough concentrations above, at and below target range were computed. Peak concentrations of 5 -12 mg/L 1,4 and trough concentrations ,0.5 mg/L 2,4 were chosen as targets for the proposed dosing guideline and the proportion of patients reaching trough concentrations ,1 mg/L was calculated. As aminoglycoside efficacy has been linked to exposure, 9 in addition, the cumulative AUC for 1 week of treatment was calculated according to the proposed dosing guideline to illustrate the uniformity of exposure across the patients.
For the simulations, a recently developed model for neonatal pharmacokinetics of gentamicin, tobramycin, amikacin, netilmicin and vancomycin was used. 8 In this model, clearance proved dependent on birth weight, representing antenatal maturation, on post-natal age, representing postnatal maturation, and on exposure to ibuprofen (decreasing clearance by 16%). Volume of distribution was dependent on current body weight. 8 To be able to perform simulations for the entire preterm and term neonatal population, covariate data on birth weight, post-natal age, current weight and ibuprofen status were extracted from previously published studies. 5 -7,10 This resulted in a combined dataset of 1854 patients with an average birth weight of 2100 g (range 390 -5200 g, SD 1100 g), an average current body weight of 2100 g (range 390 -5400 g, SD 1100 g) and an average post-natal age of 1.7 days (range 0 -27 days, SD 2.7 days), with 206 (11%) of the patients receiving ibuprofen for closure of a persistent ductus arteriosus. From the collected dataset, 5000 individuals with a post-natal age ,28 days were randomly sampled with replacement.
Simulations were performed with NONMEM 7.3 using GFortran 4.8.1.
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Data manipulation was performed with R software version 3.1.1.
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Results Table 1 shows that the existing dosing guidelines resulted in adequate peak concentrations in most of the cases (75% -88%), as did the proposed dosing guideline (82% and 91%). However, the four existing dosing guidelines also resulted in a high percentage of patients reaching trough concentrations above target, which is associated with renal and ototoxicity ( Table 1 ). The proposed new dosing guideline (Table 2 ) not only reaches target trough concentrations in 62% -67% of the cases (Table 1) , thereby comparing favourably with, for instance BNFc with percentages as low as 10%-15% (Figure 1 ), but also performs consistently across the observed covariate range of birth weight, current body weight and post-natal age, as shown in Figure 2 . Approximately 95% of the predicted trough concentrations are ,1 mg/L (Figure 2 ). Figure S1 shows that, even though the dosing protocol has been optimized for the attainment of peak and trough concentrations, it results in uniform 1 week cumulative AUC values for all subpopulations.
Discussion
In this work, the performance of commonly used gentamicin and tobramycin dosing guidelines for neonates was evaluated in terms of target peak and trough concentrations and AUC. Currently, neonates are dosed according to one of the available guidelines, after which TDM is performed and subsequent doses are adapted. As none of the evaluated guidelines performed well across the heterogeneous group of neonates varying in weight between 390 and 5200 g, an optimized dosing guideline was proposed, potentially leading to a reduced need for dose adaptation after TDM in this special population. It is emphasized Valitalo et al.
that these dosing guidelines are proposed for neonates without renal insufficiency. Even though there is an abundance of both dosing guidelines 1 -4 and pharmacokinetic models, the available models have only rarely been translated to clinical practice. 5, 6 An important finding of this study is the need for a different dose for gentamicin versus tobramycin (4.5 versus 5.5 mg/kg, respectively). This finding can be explained by the fact that tobramycin clearance and volume of distribution are higher than the respective pharmacokinetic parameters for gentamicin in neonates. 8 It has also been documented that gentamicin is more nephrotoxic than tobramycin. 13, 14 We consider this a further indication that the two drugs require different doses.
In this work, dosing intervals of up to 72 h are proposed, whereas the highest dosing interval that we are aware of in an existing dosing guideline is 60 h. 15 There is a general historical trend in gentamicin and tobramycin dosing, moving from multipledaily to once-daily dosing in adults 16, 17 and towards even less frequent dosing in neonates. 5 Given this gradual shift, we propose that the most premature neonates need yet longer dosing intervals. Despite the longer dosing interval in the proposed dosing protocol, the predicted cumulative AUC is not decreased for the most premature neonates ( Figure S1 ). Further, this cumulative AUC is not based on merely peak and trough samples; rather, it is based on a validated two-compartment pharmacokinetic model that is able to describe the full time course of drug concentrations. 7, 8 In conclusion, this work provides model-based dosing guidelines for gentamicin and tobramycin, which reflect state-of-the-art knowledge about the pharmacokinetics of these drugs and are also practical, minimizing the risk of dosing errors. Simplicity and ease of use (i.e. by restricting dosing intervals to multiples of 12 h) were considered a priority when devising the proposed dosing guideline. Simpler dosing guidelines are associated with fewer dosing errors than more complex ones. 18 Prospective validation in clinical studies of these dosing guidelines is needed to evaluate efficacy and safety of these model-based dosing guidelines.
